The Valens Company (TSX:VLNS, OTCQX:VLNCF) Inc said it has entered into a manufacturing partnership with Montreal Cannabis Médical Inc (MTL) to provide manufacturing and extraction services for MTL's pre-rolls and vapes.
Valens noted it expects the contract to begin at the end of the first quarter of fiscal 2022.
“MTL has demonstrated the kind of success, consistency and quality that The Valens Company (TSX:VLNS, OTCQX:VLNCF) looks for in a partner,” CEO Tyler Robson said in a statement.
READ: The Valens Company inks two agreements with PMI Mexico, one of the leading drug suppliers to the Mexican government
“We are excited to expand our presence with one of the fastest growing and reputable flower consumer brands in Canada,” Robson added.
MTL CEO Richard Clement also commented, saying: “Valens not only has one of the broadest ranges of manufacturing capabilities but also shares the same commitment to consumers and quality that we do.”
MTL is a flower first, craft cannabis company with a five-step process that includes an award-winning hydroponic system, hang-drying, and hand-trimming.
Since its adult-use market launch in October 2020, MTL has emerged as one of Canada's fastest-growing dried flower consumer brands, placing in the top five in dried flower sales in most provinces.
The Valens Company (TSX:VLNS, OTCQX:VLNCF) is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. It provides proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer-packaged goods.
The company's products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation.
Contact Sean at sean@proactiveinvestors.com